IP Library Granted Patent US 7,868,147
Granted Patent B2
US 7,868,147 · App. 10/570,355 · Granted Jan 11, 2011

Fluorescent probe

Assignees: Tetsuo Nagano; Sekisui Medical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,868,147
App. No.
10/570,355
Granted
Jan 11, 2011
Kind
B2
Abstract

A fluorescent probe which is represented by the following formula (I): (wherein, R 1 represents a monovalent substituent other than hydrogen atom, carboxy group, or sulfo group; R 2 represents hydrogen atom, or a monovalent substituent; R 3 and R 4 each independently represents hydrogen atom or a halogen atom; and R 5 represents a monovalent group which is cleaved by contact with a measuring object, provided that a combination of R 1 and R 2 is selected so that the oxidation potential of the benzene ring to which they bind makes (1) the compound represented by the formula (I) substantially no fluorescent before the cleavage, and (2) a compound after the cleavage, which is derived from the compound represented by the formula (I), substantially highly fluorescent after the cleavage).

Claims (22)

1. A fluorescent probe which is represented by the following formula (I):

wherein, R 1 represents a lower alkyl group or a lower alkoxy group; R 2 represents hydrogen atom, a lower alkyl group or a lower alkoxy group; R 3 and R 4 each independently represents hydrogen atom or a halogen atom; and R 5 represents a monovalent group which is cleavable by contact with an enzyme, provided that a combination of R 1 and R 2 is selected so that the oxidation potential of the benzene ring to which they bind makes:

(1) the compound represented by the formula (I) substantially not fluorescent before the cleavage, and

(2) a compound after the cleavage, which is derived from the compound represented by the formula (I), substantially highly fluorescent after the cleavage.

2. The fluorescent probe according to claim 1 , wherein R 1 is a lower alkyl group, and R 2 is a lower alkoxy group.

3. The fluorescent probe according to claim 1 , wherein R 1 is a lower alkyl group, and R 2 is a lower alkoxy group at the para-position relative to the xanthene ring residue.

4. A fluorescent probe which is represented by the following formula (I):

wherein, R 1 represents a monovalent substituent other than hydrogen atom, carboxy group, or sulfo group; R 2 represents hydrogen atom, or a monovalent substituent; R 3 and R 4 each independently represents hydrogen atom or a halogen atom; and R 5 is phosphono group cleavable by a phosphatase, provided that a combination of R 1 and R 2 is selected so that the oxidation potential of the benzene ring to which they bind makes:

(1) the compound represented (I) substantially not fluorescent before the cleavage, and

(2) a compound after the cleavage, which is derived from the compound represented by the formula (I), substantially highly fluorescent after the cleavage.

5. A fluorescent probe which is represented by the following formula (I):

wherein, R 1 represents a monovalent substituent other than hydrogen atom, carboxy group, or sulfo group; R 2 represents hydrogen atom, or a monovalent substituent; R 3 and R 4 each independently represents hydrogen atom or a halogen atom; and R 5 is a residue of a saccharide derivative cleavable with a saccharide hydrolase, provided that a combination of R 1 and R 2 is selected so that the oxidation potential of the benzene ring to which they bind makes:

(1) the compound represented by the formula (I) substantially not fluorescent before the cleavage, and

(2) a compound after the cleavage, which is derived from the compound represented by the formula (I), substantially highly fluorescent after the cleavage.

6. The fluorescent probe according to claim 5 , wherein R 5 is β-galactopyranosyl group.

7. The fluorescent probe according to claim 5 , wherein R 5 is β-galactopyranosyl group, and R 2 is a carboxy-substituted alkoxy group.

8. A fluorescent probe which is represented by the following formula (I):

wherein, R 1 represents a monovalent substituent other than hydrogen atom, carboxy group, or sulfo group; R 2 represents hydrogen atom, or a monovalent substituent; R 3 and R 4 each independently represents hydrogen atom or a halogen atom; and R 5 is a group containing a cyclic amide cleavable with a β-lactamase, provided that a combination of R 1 and R 2 is selected so that the oxidation potential of the benzene ring to which they bind makes:

(1) the compound represented by the formula (I) substantially not fluorescent before the cleavage, and

(2) a compound after the cleavage, which is derived from the compound represented by the formula (I), substantially highly fluorescent after the cleavage.

9. The fluorescent probe according to claim 8 , wherein the group containing a cyclic amide is a group represented by the following formula;

10. The fluorescent probe according to claim 7 , wherein R 2 is 4-carboxybutoxy group.

Assignments (2)
CHANGE OF NAME Recorded Nov 29, 2010
From: DAIICHI PURE CHEMICALS CO., LTD.
To: SEKISUI MEDICAL CO., LTD.
Reel/Frame 025428/0553 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2007
From: NAGANO, TETSUO; KAMIYA, MAKO; URANO, YASUTERU
To: NAGANO, TETSUO; DAIICHI PURE CHEMICALS CO., LTD.
Reel/Frame 019065/0591 →
Priority Claims (1)
JP 2003-314041 · Sep 5, 2003 · national
Continuity (1)
Related Publication 20080014602A1 · Jan 17, 2008